Isomorphic Labs 完成 50 亿美元 C 轮融资
Demis Hassabis 创立的 Isomorphic Labs 拿下 50 亿美元 C 轮,Greenoaks、红杉、a16z 联合出手,Alphabet 继续跟投。这笔钱直接投向用 AI 设计新药的管线推进,和 Insitro、Recursion 这些同行比,它背靠 DeepMind 的蛋白质结构技术。关注 AI 制药方向的投资人和生物信息开发者都该看看。
Isomorphic Labs 宣布完成 50 亿美元 C 轮融资,投资方包括 Greenoaks、Sequoia Capital 和 Andreessen Horowitz,Alphabet 继续跟投。该公司由 Demis Hassabis 创立,专注用 AI 设计和开发新药。这笔融资规模在 AI 制药领域属于头部水平,显示资本对 AI 驱动药物研发的持续押注。
公司核心方向是把 AlphaFold 系列积累的蛋白质结构预测能力延伸到药物设计环节,用计算方法缩短从靶点到候选分子的路径。融资资金预计将用于推进其内部药物管线的研发,包括临床前与临床试验阶段的开支。
对行业而言,50 亿美元的融资额意味着 AI 制药公司进入重投入竞争阶段,与 Insitro、Recursion 等公司同场竞技。对开发者来说,这也说明制药、生命科学与基础模型的交叉是当前大额融资集中的方向之一。
Isomorphic Labs raised $5 Billion in Series C funding from Greenoaks, Sequoia Capital and Andreessen Horowitz, with continued investment from Alphabet.
> Isomorphic Labs, founded by Demis Hassabis, is focussed on designing and developing new medicines with AI, ushering in a new era of biomedical breakthroughs.
Drug development is a huge area that everyone is expecting to get pushed forward by AI.
Soon? 👀
This report is categorized under AITOP's "Industry" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Key entities and technical topics under continuous tracking include Isomorphic Labs, Demis Hassabis, AI drug discovery, drug discovery.
Source attribution: curated from TestingCatalog (@testingcatalog). Cross-source corroboration: 4 independent sources have covered this development (including IT之家, kimmonismus, Tech in Asia), confirming industry-wide signal strength.